BACKGROUND: The 10-valent protein D pneumococcal conjugate vaccine (PHiD-CV) was licensed on the basis of immunogenicity studies and there are no published data on its effectiveness to prevent invasive pneumococcal disease (IPD). In the province of Quebec, Canada, PHiD-CV was introduced in the summer of 2009, replacing the 7-valent CRM197 vaccine (PCV-7). Transition to the new vaccine was recommended regardless of the number of PCV7 doses already administered. METHODS: IPD rates in children born in 2007-2010 and observed up to the end of 2010 were computed from laboratory surveillance data. The main vaccine used for the infant primary immunization series (mainly 2 doses at 2-4 months) and the toddler (12 months) booster dose was inferred from the Quebec City Immunization Registry data. RESULTS: IPD rates were significantly lower in the cohorts exposed to PHiD-CV (35/100,000 person-years) as compared with those exposed to PCV-7 (64/100,000 person-years; p=0.03). There was no breakthrough vaccine-type IPD case among children who had received ≥2 PHiD-CV doses for the primary series or a single PHiD-CV dose as a booster. There was also a statistically non-significant lower frequency of 19A and other non-vaccine types IPD cases in children exposed to 2+1 PHiD-CV doses as compared with those exposed to PCV-7. INTERPRETATION: Results are compatible with a high level of protection induced by PHiD-CV against IPD caused by homologous serotypes.
BACKGROUND: The 10-valent protein D pneumococcal conjugate vaccine (PHiD-CV) was licensed on the basis of immunogenicity studies and there are no published data on its effectiveness to prevent invasive pneumococcal disease (IPD). In the province of Quebec, Canada, PHiD-CV was introduced in the summer of 2009, replacing the 7-valent CRM197 vaccine (PCV-7). Transition to the new vaccine was recommended regardless of the number of PCV7 doses already administered. METHODS: IPD rates in children born in 2007-2010 and observed up to the end of 2010 were computed from laboratory surveillance data. The main vaccine used for the infant primary immunization series (mainly 2 doses at 2-4 months) and the toddler (12 months) booster dose was inferred from the Quebec City Immunization Registry data. RESULTS: IPD rates were significantly lower in the cohorts exposed to PHiD-CV (35/100,000 person-years) as compared with those exposed to PCV-7 (64/100,000 person-years; p=0.03). There was no breakthrough vaccine-type IPD case among children who had received ≥2 PHiD-CV doses for the primary series or a single PHiD-CV dose as a booster. There was also a statistically non-significant lower frequency of 19A and other non-vaccine types IPD cases in children exposed to 2+1 PHiD-CV doses as compared with those exposed to PCV-7. INTERPRETATION: Results are compatible with a high level of protection induced by PHiD-CV against IPD caused by homologous serotypes.
Authors: Jukka Jokinen; Hanna Rinta-Kokko; Lotta Siira; Arto A Palmu; Mikko J Virtanen; Hanna Nohynek; Anni Virolainen-Julkunen; Maija Toropainen; J Pekka Nuorti Journal: PLoS One Date: 2015-03-17 Impact factor: 3.240
Authors: Mirjam J Knol; Gertjan H J Wagenvoort; Elisabeth A M Sanders; Karin Elberse; Bart J Vlaminckx; Hester E de Melker; Arie van der Ende Journal: Emerg Infect Dis Date: 2015-11 Impact factor: 6.883
Authors: Carla Magda Allan S Domingues; Jennifer R Verani; Ernesto Issac Montenegro Renoiner; Maria Cristina de Cunto Brandileone; Brendan Flannery; Lucia Helena de Oliveira; João Barberino Santos; José Cássio de Moraes Journal: Lancet Respir Med Date: 2014-04-10 Impact factor: 30.700
Authors: Richard A Adegbola; Rodrigo DeAntonio; Philip C Hill; Anna Roca; Effua Usuf; Bernard Hoet; Brian M Greenwood Journal: PLoS One Date: 2014-08-01 Impact factor: 3.240
Authors: Timo Vesikari; Aino Forsten; Ilkka Seppä; Tarja Kaijalainen; Taneli Puumalainen; Anu Soininen; Magali Traskine; Patricia Lommel; Sonia Schoonbroodt; Marjan Hezareh; Marta Moreira; Dorota Borys; Lode Schuerman Journal: J Pediatric Infect Dis Soc Date: 2016-04-28 Impact factor: 3.164